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Abstract
Purpose: The oncogenic miR-155 is upregulated in many
human cancers, and its expression is increased in more aggressive
and therapy-resistant tumors, but the molecular mechanisms
underlying miR-155-induced therapy resistance are not fully
understood. The main objectives of this study were to determine
the role ofmiR-155 in resistance to chemotherapy and to evaluate
anti-miR-155 treatment to chemosensitize tumors.
Experimental Design: We performed in vitro studies on cell
lines to investigate the role of miR-155 in therapy resistance. To
assess the effects of miR-155 inhibition on chemoresistance, we
used an in vivo orthotopic lung cancer model of athymic nude
mice, which we treated with anti-miR-155 alone or in combina-
tion with chemotherapy. To analyze the association of miR-155
expression and the combination ofmiR-155 and TP53 expression
with cancer survival, we studied 956 patients with lung cancer,
chronic lymphocytic leukemia, and acute lymphoblastic
leukemia.
Results: We demonstrate that miR-155 induces resistance to
multiple chemotherapeutic agents in vitro, and that downregula-
tion ofmiR-155 successfully resensitizes tumors to chemotherapy
in vivo.We show that anti-miR-155-DOPC can be considered non-
toxic in vivo. We further demonstrate that miR-155 and TP53 are
linked in a negative feedback mechanism and that a combination
of high expression of miR-155 and low expression of TP53 is
significantly associated with shorter survival in lung cancer.
Conclusions: Our findings support the existence of an miR-
155/TP53 feedback loop, which is involved in resistance to
chemotherapy and which can be specifically targeted to over-
comedrug resistance, an important cause of cancer-related death.
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Introduction
Resistance to therapy is the leading cause of failure to respond
to chemotherapeutic drugs that leads to the high mortality in
cancer (1, 2). Despite decades of research, only modest advances
have been made in developing strategies to overcome resistance
(3). The addition of non-coding RNAs (ncRNAs) to the ever-
expanding set of genes deregulated in cancer (4, 5) offers the
opportunity to deeper understand these mechanisms and the
hope to eradicate chemoresistance. Non–small cell lung cancer
(NSCLC) and chronic lymphocytic leukemia (CLL) are the most
frequent adult solid and hematological malignancies in the
Western world, respectively (2), and resistance to therapy is a
very significant medical issue in these patients. Virtually all
patients with NSCLC will eventually develop resistance to the
chemotherapeutic agents they are exposed to (6), and all patients
with CLL requiring treatment, including the standard-of-care
chemotherapy-based fludarabine, cyclophosphamide, and ritux-
imab (FCR) treatment, are expected to relapse (7). The poorest-
prognosis CLL subgroup is characterized by deletions of chromo-
some 17p (del17p), the genomic locus of TP53, having an overall
survival of less than 2 years (8, 9). The tumor suppressor gene
TP53 is frequently deleted or mutated in human cancers and is
involved in the development of drug resistance by cancer cells
(10).
MicroRNAs (miRNAs) are small ncRNAs that regulate the
expression of protein coding genes (11).MiR-155 is a well-known
oncogenic miRNA, which is upregulated in a wide variety of
human cancers (12, 13), especially in more aggressive and ther-
apy-resistant tumors (14, 15). For example, we identified a
signature of deregulated miRNAs in patients with CLL and 17p
deletion, versus patients with normal genotype, having good
prognosis (16). In the 17p deletion group, miR-155 was the most
upregulated miRNA (16). Moreover, we and others have dem-
onstrated that miR-155 has prognostic significance in multiple
types of tumors, including leukemia (17, 18) and lung cancer
(19, 20).
Overexpression of miR-155 has been associated with drug
resistance in several human cancers, including breast cancer,
B-cell lymphoma, and colon cancer (14, 21, 22), but the molec-
ular mechanisms through which miR-155 increases cancer cell
resistance to treatment are not fully understood. Therefore, the
main objectives of this study were to determine the molecular
mechanism through which miR-155 induces resistance to che-
motherapy and to evaluate anti-miR-155 treatment to chemo-
sensitize tumors.Wedemonstrate that overexpression ofmiR-155
induces resistance to chemotherapy, which can be reversed upon
miR-155 inhibition. We show that anti-miR-155-DOPC does not
induce adverse events and can be considered non-toxic in vivo. We
further identify a miR-155/TP53-negative regulatory feedback
loop that affects the development of cancer drug resistance. The
inverse expression correlation between miR-155 and TP53 tran-
scripts is additionally supported by survival data from four lung
cancer cohorts, inwhichwe show that high expression ofmiR-155
and low expression of TP53 are associated with shorter survival,
further confirming the involvementofmiR-155 inTP53-mediated
resistance mechanisms.
Materials and Methods
Patient samples
The origin of all patient datasets is presented in Table 1. The
total number of patients included in the survival analyses was
956. Both analyzed CLL subgroups were previously described:
CLL-NEJM (23) and CLL-Clin Cancer Res (24). Clinical charac-
teristics of bothCLL cohorts canbe found in Supplemental Tables.
Twenty-four NSCLC samples were collected at the Istituto
Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)
IRCCS, Italy (NSCLC-Italy), 58 lung adenocarcinoma samples
were collected at The University of Texas MD Anderson Cancer
Center (lung adenocarcinoma-MDACC), and 52 ALL samples
were collected at MDACC (ALL-MDACC). Clinical characteristics
of both lung cancer datasets and the ALL dataset can be found in
Supplementary Tables S2 and S3, respectively. All patients pro-
vided written informed consent prior to inclusion in the study,
and collection of the samples was approved by the institutional
review board at each institution (IRST Srl IRCCS, and MDACC).
All thework described has been carried out in accordancewith the
Declaration of Helsinki. In addition, the TCGA datasets for lung
adenocarcinoma (n ¼ 343) and lung squamous cell carcinoma
(n ¼ 192) were downloaded from the data portal at https://gdc.
cancer.gov/ (currently https://gdc.cancer.gov), and survival anal-
ysis was performed (Table 1).
Cell culture, transfection, and treatment
Cell lines. Lung cancer cell lines A549, H460, H2009, and H1299
and leukemia cell lines REH and JM1 were purchased from the
American TypeCultureCollection (ATCC) and cultured following
the recommendations in the Product Information Sheet (ATCC).
REH cells with TP53 knockdown (REH shp53) were generated by
retroviral transduction with the gene-specific shRNA transfer
vector pMKO.1 puro p53 shRNA 2 (plasmid 10672, Addgene),
as previously described (25). REH cells transfectedwith the empty
vector pMKO.1 puro GFP shRNA (REH wt) were used as negative
controls. Cell lineswere authenticated via STRDNAfingerprinting
and tested for mycoplasma contamination with the MycoAlert
Mycoplasma Detection Kit (Lonza) at the time they were cultured
for the experiments performed in frame of this research.
miRNA mimics/inhibitor transfection. Transfections were per-
formed with 100 nmol/L of the precursor molecules (hsa-miR-
155-5p pre-miRNA precursor or pre-miRNA precursor negative
Translational Relevance
Resistance to therapy is an important issue in the treatment
of cancer, responsible for many cancer-related deaths. Despite
decades of research into overcoming this resistance, only
modest advances have beenmade, and the resistancemechan-
isms remain poorly understood. This is the first report of a
miR-155/TP53-negative feedback mechanism in which there
is a direct targeting of TP53 bymiR-155, and which is involved
in the resistance to multiple chemotherapeutic drugs used in
the treatment of lung cancer and leukemias. The finding that
treatment with anti-miR-155 can reverse chemoresistance in
vivo and that anti-miR-155-DOPC is not toxic in vivo supports a
potential clinical use of anti-miR-155 therapy in human
clinical trials of various cancer types as an addition to current
chemotherapy regimens in order to overcome cancer-enacted
resistance mechanisms.
Van Roosbroeck et al.
Clin Cancer Res; 23(11) June 1, 2017 Clinical Cancer Research2892
on March 13, 2019. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst November 30, 2016; DOI: 10.1158/1078-0432.CCR-16-1025 
control #1), 200 nmol/L of the miRVana inhibitors (miRVana
hsa-miR-155 inhibitor and miRVana inhibitor negative control
#1), and Lipofectamine 2000 reagent or Lipofectamine RNAiMAX
reagent, respectively (Life Technologies), according to the
manufacturer's instructions. MiRNA transfection efficiencies were
evaluated by qRT-PCR.
miR-155 lentivirus infection. pMIRNA1—miR-155 and
pMIRNA1—Empty Vectors were obtained from System Bios-
ciences, and viral particles were produced according to the
manufacturer's instructions. A549, REH wt, REH shp53 and JM1
cells were infected with the miR-155 lentivirus with an efficiency
of approximately 50% as determined by GFP measurement by
flow cytometry. Empty lentivirus (LVEV, lentivirus empty vector)
was used as a negative control for the experiments.
Drug treatment. Cisplatin (CDDP) was obtained from the oncol-
ogy pharmacy ofMDACC and S.r.l. IRCCS as an aqueous solution
at a concentration of 1 mg/mL corresponding to 3.3 mmol/L.
Exposures ranged from 0.01 to 10 mmol/L. Doxorubicin (hydro-
chloride) was purchased as a powder from Sigma-Aldrich and
resuspended in dimethyl sulfoxide (DMSO) (Sigma-Aldrich) to a
stock concentration of 1.78mmol/L. Exposures ranged from 0.01
to 0.5 mmol/L.
RNA extraction and quantitative real-time PCR
RNA was isolated with TRIzol (Life Technologies), or with
mirVana miRNA Isolation Kit (Ambion, Life Technologies),
according to themanufacturer's instructions. MiR-155 expression
was analyzed with TaqMan miRNA Assays (Life Technologies).
cDNA was synthesized using gene-specific stem-loop reverse
transcription primer and the TaqMan microRNA reverse-tran-
scription kit (Life Technologies). Real-time qRT-PCR was carried
out in an Applied Biosystems 7500 Real-Time PCR System
(Applied Biosystems, Life Technologies) or on a Bio-Rad CFX384
Real-Time PCR Detection System (Bio-Rad Laboratories). Experi-
ments were performed in triplicate and normalized to RNU44,
U6, or RNU6B. Relative expression levels were calculated with the
comparative Ct method (DDCt).
Protein extraction and Western blotting
Protein extraction and Western blotting were performed as
previously described (26, 27). The following primary antibodies
were used: anti-Vinculin clone FB11mousemonoclonal antibody
(Biohit, Sartorius), anti-Human/Mouse/Rat p53 goat polyclonal
antibody (R&D Systems), anti-p21WAF1 Ab-3 (Clone DCS-60.2)
mouse monoclonal antibody (Lab Vision, Thermo Fisher Scien-
tific), anti-p21Waf1/Cip1 (DCS60)mousemonoclonal antibody
(Cell Signaling Technology) and anti-TP53DINP1 rabbit poly-
clonal antibody (OriGene). Western blots were quantified with
Photoshop CS6 (Adobe).
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed
with the EZ-ChIP Chromatin Immunoprecipitation kit (EMD
Millipore) and the rabbit polyclonal antibody p53 (FL-393)
(Santa Cruz Biotechnology) according to the manufacturer's
instructions. The TP53 binding sites in miR-155 (TP53 BS1/2
and TP53 BS3) were amplified with RedTaq DNA polymerase
(Sigma-Aldrich) using the primers below and analyzed on a 2%
agarose gel.Ta
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TP53 BS1/2 ChIP FW 50-GATCAAAGGATTCTCACCTGGG-30
TP53 BS1/2 ChIP RV 50-ATCTGAACTACCTGGTCAGCCTGT-30
TP53 BS3 ChIP FW 50-AGCAGGGTAAATAACATCTGACAGC-30
TP53BS3ChIPRV 50-CATATGGAGGAAGAAACAGGCTTAG-30
Luciferase assay and mutagenesis
Identification of putative TP53 binding sites within a 10-kb
genomic region surrounding miR-155 was performed by a TP53-
binding site prediction program, which we developed earlier
(28, 29). The identified TP53 binding site BS3 downstream of
the miR-155 gene was cloned in the pGL4.23 (luc2/minP) vector
(Promega) with the following primers (underlined are the added
restriction sites):
TP53 BS3 FW 50-GCGGTACCGGGAAACTGAAAGGCTATGAA-30
TP53 BS3 RV 50-GCGCTAGCCCCCATATGGAGGAAGAAAC-30
A549 cells were seeded at 50,000 cells/well in 24-well
plates and cotransfected with the pGL4.23 vector containing
the predicted TP53 binding site, the pCMV6-XL5-TP53 expres-
sing vector (OriGene) and the pGL4.74 (hRluc/TK) vector
containing renilla luciferase. Twenty-four hours after trans-
fection, the samples were analyzed with the Dual-Luciferase
Reporter Assay System (Promega) in a Glomax 96 Microplate
Luminometer (Promega) as described in the manufacturer's
manual. Mutagenesis of the TP53 recognition sequence BS3
was performed with the QuickChange XL Site-Direct Muta-
genesis Kit (Stratagene, Agilent Technologies), which deleted
a portion of the TP53 consensus sequence, according to the
manufacturer's instructions, and with the following primers:
TP53BS3-DELFW 50-CATATTTGAAATGTCTAGGTTCAAGTT-
CAATAGCTTAGCC-30
TP53 BS3-DEL RV 50-GGCTAAGCTATTGAACTTGAACCTAGA-
CATTTCAAATATG-30
Identification of putative miR-155 binding sites in TP53 was
performed with RNAhybrid (v2.2; ref. 30). The identified miR-
155 binding sites in TP53 [in coding sequence, BS-CDS; in 30
untranslated region (UTR), BS-UTR] were cloned in a pGL3
Control vector (Promega)with the following primers (underlined
are the added restriction sites):
miR-155 BS-CDS FW 50-GGACTAGTCATGAGCGCTGCTCA-
GATAG-30
miR-155 BS-CDS RV 50-TCCCCGCGGGCCCATGCAGGAAC-
TGTTA-30
miR-155 BS-UTR FW 50-GGACTAGTAAGGAAATCTCACCC-
CATCC-30
miR-155 BS-UTR RV 50-TCCCCGCGGAAGGCTGCAGTAAGC-
CAAGA-30
H1299 and H460 were seeded and transfected as mentioned
above. Luciferase assays and mutagenesis of the identified
binding sites were carried out as mentioned above. The fol-
lowing primers, which deleted the miR-155 binding site, were
used:
miR-155 BS-CDS-DEL FW
50-GGTCTGGCCCCTCCTCAGCATTTGCGTGTGGAGTATTT-
GG-30
miR-155 BS-CDS-DEL RV
50-CCAAATACTCCACACGCAAATGCTGAGGAGGGGCCAGA-
CC-30
miR-155 BS-UTR-DEL FW
50-GAGACTGGGTCTCGCTTTGTGATCTTGGCTTACTGCAG-
CC-30
miR-155 BS-UTR-DEL RV
50-GGCTGCAGTAAGCCAAGATCACAAAGCGAGACCCAGTC-
TC-30
Drug resistance assays
MTT-based in vitro toxicology assay. Five thousand cells treated
with different drug concentrations were plated in a 96-well plate
(four replicates per condition). After 72 hours, the MTT-based In
Vitro Toxicology Assay (Sigma-Aldrich) was carried out according
to the manufacturer's instructions. Proliferation was analyzed by
measuring absorbance at 580 nm with a SpectraMax Plus Micro-
Plate Reader (Molecular Devices).
In vitro cell growth assays. Twenty-four hours after transfection
with anti-miR-155-5p precursor or negative control, A549 cells
were treated with 5 mmol/L CDDP for 6h followed by a 24-, 48-,
72-, and 96-hour washout. JM1 stable clones (JM1-LVEV and
JM1-LVEV) were treated with 1 mmol/L CDDP for 6 hours fol-
lowed by a 24, 48, 72, and 96 hours washout, while REH stable
clones (REHwt-LVEV, REHwt-155LV, REH shp53-LVEV and REH
shp53-155LV) were treated with 0.1 mmol/L doxorubicin for 1
hour followed by a 24-, 48-, 72-, and 96-hour washout. Cells were
counted 24, 48, 72, and 96 hours after treatment with the Trypan
Blue exclusion assay. Experiments were carried out in triplicates
and minimum two independent experiments were performed.
In vitro proliferation assay. Twenty-four hours after transfection
with hsa-miR-155 inhibitor or negative control, H2009 cells were
treated with 10 mmol/L CDDP for 6 hours followed by a 24-, 48-,
and 72-hour washout. Cell proliferation was assessed by the
CellTiter-Glo Luminescent Cell Viability Assay (Promega) accord-
ing to the manufacturer's instructions.
Clonogenic assay. A549 cell stably infected with empty lentivirus
(A549-LVEV) or with miR-155 overexpressing lentivirus (A549-
155LV) were untreated (negative control) or treated with 5 mmol/
L CDDP for 6 hours. Twenty-four hours after treatment, cells were
trypsinized, and 1,000 cells were plated in triplicates in 60-mm
dishes. After 10 days, colonies were fixed with 80% methanol,
stained with 0.25% 1,9-dimethyl-methylene blue in 50% ethanol
(Sigma-Aldrich), and individual colonies were counted.
In vivo orthotopic mouse models
All mice used in this study were housed and maintained
according to guidelines set by the American Association for
Accreditation of Laboratory Animal Care and the US Public
Health Service policy on Human Care and Use of Laboratory
Animals. The mouse study was approved and supervised by The
University of Texas MD Anderson Cancer Center Institutional
Animal Care and Use Committee, which adheres to the ARRIVE
guidelines for in vivo experiments. The number of mice was
determined based on previous experience with these kind of
orthotopic mouse models (31–33), as well as on the power
calculations that a group size of 10 would give 80% power to
detect changes of 1.686 and 1.638 standard deviations ormore in
a single group when five, respectively four, groups were consid-
ered (a ¼ 0.05). Female athymic nude mice between 6 and 8
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weeks of age and with a weight of 20–25 g were purchased from
the National Cancer Institute, Frederick Cancer Research and
Development Center (Frederick, MD).
Orthotopic lung cancer model. Control anti-miR (mirVanamiRNA
inhibitor negative control #1; Life Technologies) or anti-miR-155
(hsa-miR-155 mirVana miRNA inhibitor; Life Technologies) was
incorporated into DOPC nanoliposomes for in vivo delivery as
previously described (34). The intrapulmonary injections of A549
cells stably infected with either lentivirus containing empty lenti-
viral vector (A549-LVEV) orwith lentivirus containing amiR-155-
overexpressing lentiviral vector (A549-155LV) were performed as
previously described (32).Oneweek after injection, themicewere
randomized in four (initial experiment) or five (second, inde-
pendent experiment) groups, and treatment with CDDP and/or
nanoliposomes (either negative control or miR-155 inhibiting)
was started. CDDP (160 mg/mouse) was administered i.p. once a
week, while liposomal nanoparticles (200 mg/kg) were adminis-
tered i.v. twice a week. The treatment schedules can be found in
Fig. 2A and Supplementary Fig. S2A. In the initial experiment, out
of 40 mice initially injected with A549 cells, two mice died from
surgery, and one died from CDDP toxicity 3 weeks after start of
treatment. In the second, independent experiment, out of 50mice
initially injected with A549 cells, six died from surgery, and two
died from CDDP toxicity 3 to 4 weeks after the start of treatment.
After 4, respectively 5, weeks of treatment, themice were sacrificed
and analyzed macroscopically as previously described (32).
MiR-155 expression in tissue sections was analyzed by in situ
hybridization as previously described (31). Double-digoxigenin
(DIG)-labeled locked nucleic acid (LNA) probes for miR-155
(Exiqon) were used.
Cell proliferation, angiogenesis, and microvesicle density and
apoptosiswereassessedbyKi-67orCD31 immunostaining,orwith
theTUNELassay aspreviouslydescribed(31,35).Ki-67,CD31, and
TUNEL-positive cells were counted in three random fields per slide,
and five slides per group were analyzed at 200 magnification.
The expressionof TP53was determinedby immunohistochem-
ical analysis using freshly cut frozenmouse tissue. The slides were
fixed in cold acetone/acetone þ chloroform 1:1/acetone, and
blocked with cold-water fish skin gelatin 4% (Electron Microsco-
py Sciences) in PBS. Slides were incubated overnight at 4C with
primary antibody anti-Tp53 (Cell Signaling Technology), washed
with PBS, incubatedwith the goat anti-rabbit Alexa 594 secondary
antibody (The Jackson Laboratory), washed and counterstained
with Hoechst. The expression of TP53 was counted in three
random fields per slide (one slide per mouse, five slides per
group) at 200 magnification.
In vivo toxicology assessment of anti-miR-155
Male CD-1 IGSmice with a weight of 35 to 40 g were purchased
from Charles Rivers and randomized into two groups (anti-miR-
NCand anti-miR-155;n¼ 17/group). Liposomal control anti-miR-
DOPC (anti-miR-NC-DOPC) and anti-miR-155-DOPC nanopar-
ticleswere injected into the respectivemice i.v. via tail-vein injection
at a concentration of 200 mg/kg of body weight. Body weight was
measured before and after treatment and was not significantly
different between both groups. After 72 hours of treatment, mice
were euthanized by exsanguination following IACUC approved
protocols. Blood samples and tissues (fixed and embedded in
paraffin) were collected at necropsy for further analyses. Blood
samples were processed for blood chemistry and hematology.
Blood chemistry analyses included blood urea nitrogen content
(BUN), aspartate aminotransferase (AST), alanine aminotransfer-
ase (ALT), alkaline phosphatase (ALP), and creatinine and lactic
dehydrogenase (LDH) and were evaluated on an Integra 400 Plus
analyzer (Roche Diagnostics). Hematology analyses consisted of
complete blood count [white blood cell (WBC) count, red blood
cell (RBC) count, hemoglobin, hematocrit, average volume of RBC
(mean corpuscular volume or MCV), average amount of hemo-
globin in one RBC (mean corpuscular hemoglobin or MCH),
average concentration of hemoglobin in one RBC (MCH concen-
tration or MCHC), red cell distribution width (RDW), platelet and
mean platelet volume (MPV)], as well as WBC differential count
[levels of segmented neutrophils, lymphocytes, monocytes, eosi-
nophils, basophils and large unstained cells (LUC)], and were
evaluated on an Avida 120 Hematology System (Siemens Healthi-
neers). Paraffin-embedded tissue sections were stained with hema-
toxylin and eosin (H&E) for routine histopathology.
To assess serum cytokine levels, mice were treated with single
i.v. injections of either anti-miR-NC-DOPC (n¼ 10) or anti-miR-
155-DOPC (n¼10). Seventy-twohours after injection, serumwas
collected using cardiac puncture and analyzed with a Luminex
assay (MCYTOMAG-70K-PMX/MULTIPLEX map mouse cyto-
kine/chemokine magnetic bead panel, EMD Millipore) detecting
25 proinflammatory cytokines (G-CSF, GM-CSF, IFNg , IL1a,
IL1b, IL2, IL4, IL5, IL6, IL7, IL9, IL10, IL12 (p40), IL12 (p70),
IL13, IL15, IL17, IP10, KC, MCP-1, MIP1a, MIP1b, MIP2,
RANTES, and TNFa) using a Luminex 100 system (Luminex), as
previously described (36).
Integrated function and pathway analysis
We retrieved experimentally validated miR-155 targets from
the following four databases: miRTarBase (http://mirtarbase.
mbc.nctu.edu.tw), TarBase (http://diana.imis.athena-innovation.
gr/DianaTools/), miRWalk (http://www.umm.uni-heidelberg.de/
apps/zmf/mirwalk/), andmiRecords (http://c1.accurascience.com/
miRecords/). We restricted ourselves to those targets that were
supported by strong experimental evidence, such as reporter
assay, Western blot, quantitative PCR, and immunoprecipita-
tion. Of the 248 miR-155 targets that were identified, integrated
function and pathway analysis was performed using DAVID
bioinformatics resources (http://david.abcc.ncifcrf.gov/). We
imposed a cutoff of 10% FDR to indicate a statistically signif-
icant association between a pathway and the list of mRNA
targets of miR-155. The P value and false discovery rate were
generated by a modified Fisher exact test.
TCGA data analysis
Input data were downloaded from the publicly available data
portal of The Cancer Genome Atlas Project (TCGA) at https://gdc.
cancer.gov/. Level 3 Illumina RNA-Seq and miRNA-Seq were used
for the analysis of mRNA and miRNA expression, respectively. For
miRNA-Seq data, we derived the "reads_per_million_miRNA_-
mapped" values for mature forms of each microRNA from the
"isoform_quantification" files. Patient samples with survival data
of 0 "days_to_last_follow_up" were excluded. Data for somatic
mutations of TP53 in TCGA samples were downloaded from the
cBio Portal at http://www.cbioportal.org/public-portal/.
Statistical analyses
All patient-related analyses were carried out in the R statistical
environment, version 3.0. (http://www.r-project.org/). Survival
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analyses were performed as previously described (31) with some
modifications. Briefly, for each cohort, a relationship between
miR-155/TP53 expression and overall survival was assessed as
follows. Patients were grouped into percentiles according to miR-
155 and TP53 expression. The log-rank test was employed to
determine the association between miRNA/mRNA expression
and survival. The Kaplan–Meyer method was used to generate
survival curves. The P value and the cut-off to optimally separate
the patients in high and low (min P value) miR-155 and TP53
were recorded. We then considered whether combining inverse
expression of miR-155 and TP53 would associate with survival.
We used the following procedure. A fixed cutoff for miR-155
together with a fixed cutoff for TP53 splits the cohort in four
groups corresponding to low or high miR-155 and low or high
TP53 expression. For each pair of cutoffs we contrasted the two
groups linked to a negative association: tumors with high levels of
miR-155 and low levels of TP53 versus tumors with low levels of
miR-155 and high levels of TP53. We recorded the best separation
obtained (min P value) for the pair and noticed that the difference
in median survival time between the two groups contrasted is
significantly larger than the difference between the groups clas-
sified into high/low based on the expression of miR-155 or TP53
alone. The relationship between survival and covariates (miR-155
and TP53 expression levels and available prognostic factors or
other clinical parameters)was examined using aCoxproportional
hazard model.
For lung adenocarcinoma cases withmiR-155 expression, TP53
mutational status, and survival information available, we checked
for a relationship between miR-155 expression, TP53 expression,
and overall survival in patients with wild-type TP53 and mutated
TP53 in a similar manner as described above. According to the
TP53mutational status, patients were divided into two groups: (i)
those expressing wild-type TP53 (unmutated) or harboring TP53
mutations not affecting its protein function (according to the
IARC TP53 database p53.iarc.fr), and (ii) those harboring TP53
mutations that affect TP53 protein function (according to the
IARC TP53 database p53.iarc.fr). For each group, Kaplan–Meier
overall survival curves were generated for high versus low miR-
155, and high miR-155 and low TP53 versus low miR-155 and
high TP53.
Statistical analysis of the in vitro and in vivo data was carried out
with GraphPad Prism 6 software. To verify whether data followed
a normal distribution, the Shapiro–Wilk normality test was
performed, and an unpaired t test (normal distribution) or
non-parametric Mann–Whitney–Wilcoxon test (nonnormal dis-
tribution) was applied to determine P values. All tests were two-
sided, and P values <0.05 were considered statistically significant.
Statistical significances are presented according to the following
scheme: , P < 0.05; , P < 0.01; , P < 0.001; , P < 0.0001.
Results
MiR-155 induces chemoresistance in vitro
We treated three different lung cancer and leukemia cell lines
with endogenous levels of miR-155 expression and after miR-155
overexpression (either by miR-155 precursor or miR-155 lentivi-
rus) with chemotherapeutic agents commonly used to treat
patients: the lung cancer cell line A549 with cisplatin (CDDP,
cis-diamminodichloroplatinum) (6, 37), the acute lymphoblastic
leukemia (ALL) cell line REH with doxorubicin (38), and the
immunoblastic B-cell leukemia/lymphoma cell line JM1 with
CDDP (39). As shown in Fig. 1A and B, A549, REH, and JM1
cells overexpresssing miR-155 showed a significantly better via-
bility and displayed significantly lower chemosensitivity when
undergoing treatment with CDDP or doxorubicin than cells
expressing normal levels of miR-155. In addition, we performed
a clonogenic assay for A549 cells stably overexpressing miR-155
(A549-155LV) and treated with CDDP versus control cells (A549-
LVEV) treated with CDDP. We observed a significant increase in
the number of colonies whenmiR-155was overexpressed, further
demonstrating the chemoresistance induced by miR-155
(Fig. 1C). Moreover, when we treated the H2009 lung cancer cell
line with miR-155 inhibitor and CDDP, we found that these cells
grew significantly less than H2009 cells treated with negative
control inhibitor and CDDP (Fig. 1D). Of note, when TP53
expression was abolished in REH cells by shRNA treatment, the
protective effect to chemotherapeutic agents in cells overexpres-
sing miR-155 disappeared (Fig. 1A, middle; Fig. 1B, middle).
Finally, no difference in chemosensitivity was observed after
fludarabine treatment and miR-155 overexpression in MEC1 and
MEC2 cell lines, both of which carry a deletion of the TP53 locus
(ref. 40; Supplementary Fig. S1). Altogether, these data suggest a
role of miR-155 in drug resistance in various types of cancer,
including lung cancer and leukemia, for multiple types of
chemotherapy.
MiR-155-induced chemoresistance can be reversed in vivo by
treatment with anti-miR-155-DOPC
To evaluate the in vivo involvement of miR-155 in therapy
resistance, we established anorthotopic lung cancermousemodel
by intrapulmonary injection of A549-LVEV (control) cells or with
A549-155LV (miR-155-overexpressing) cells. Two independent
experiments were carried out with four (Supplementary Fig. S2)
and five (Fig. 2) treatment groups, respectively, in which mice
were treated with negative control anti-miR (anti-miR-NC) or
with anti-miR-155 alone or in combination with CDDP, accord-
ing to the schedule in Fig. 2A; Supplementary Fig. S2A. Mice
injected with A549-LVEV cells and treated with CDDP and
anti-miR-NC showed a decrease in number of tumors, reduced
primary tumor size and a reduced aggregate mass of metastases
when compared with untreated mice injected with A549-LVEV
cells, although this decrease was not significant, indicating that
these tumors are sensitive to CDDP, as was expected (Fig. 2B and
C; Supplementary Fig. S2B–D).WhenmiR-155was overexpressed
(through injection of A549-155LV cells), the tumors became
resistant to CDDP treatment and the administration of anti-
miR-155 alone significantly reduced number of tumors, tumor
size, andaggregatemassofmetastases (Fig. 2B andC). In addition,
when anti-miR-155 was combined with CDDP treatment, the
chemotherapy resistance was almost completely reversed (Fig. 2B
and C; Supplementary Fig. S2B–D). In situ hybridization for
miR-155 showed an increase of miR-155 expression in miR-
155-overexpressing tumors treated with CDDP and anti-miR-NC,
and miR-155 levels comparable to or lower than A549-LVEV
tumors when miR-155-overexpressing tumors were treated with
anti-miR-155 alone or in combination with CDDP (Fig. 2D;
Supplementary Fig. S2E). Immunohistochemistry for Ki-67 (pro-
liferation), CD31 (angiogenesis), and the TUNEL (apoptosis)
assay suggested that miR-155, even in the presence of CDDP, is
able to induce cell proliferation and angiogenesis, and reduce
apoptosis, effects that are completely abolished when miR-155 is
inhibited (Fig. 2E; Supplementary Fig. S2F). Although treatment
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with anti-miR-155 alone resulted in a significant decrease in
proliferation and angiogenesis, and increase in apoptosis, the
effects are even more pronounced when anti-miR-155 is com-
bined with CDDP therapy (Fig. 2E). Therefore, the in vivo rever-
sion of chemoresistance by anti-miR-155 administration is con-
sistent and reproducible by independent sets of experiments.
Anti-miR-155-DOPC does not induce toxic effects in vivo
To assess the in vivo toxicity effects of anti-miR-155-DOPC, we
evaluated blood chemistry, hematology, cytokine production,
and general histology in mice injected with a single dose of either
anti-miR-NC-DOPC or anti-miR-155-DOPC (Fig. 3). Blood
chemistry analyses for metabolites to assess overall tissue damage
(Fig. 3A) and complete hematology investigation of WBC, RBC,
and platelets (Fig. 3B and C) showed no significant differences
between both groups, except for the platelet count, which was
marginally significantly higher in anti-miR-155-DOPC-treated
mice (P ¼ 0.0464; Fig. 3B). We further performed a cytokine
assay detecting 25 proinflammatory cytokines in the serum of
mice injected with either anti-miR-NC-DOPC or anti-miR-155-
DOPC. With the exception of IL12 (p40), IL17, MIP1a and
MIP1b, which showed marginally statistically significant differ-
ences, no activation of the immune system was observed (Fig.
3D). Finally, H&E histological analysis showed no inflammatory
changes inbrain, heart, kidney, liver, lung, and spleen in anyof the
groups (Fig. 3E). We previously demonstrated that DOPC lipo-
somal nanoparticles are not toxic in vivo for doses up to 20 mg/kg
for 5 consecutive days (41). These data suggest that the therapeutic
effects observed in our in vivo orthotopic mouse model are likely
caused by targeting of miR-155, rather than by immune induc-
tion, and that anti-miR-155-DOPC can be considered non-toxic
in mice.
Identification of a miR-155/TP53-negative feedback loop
miR-155 is significantly overexpressed in patients with CLL and
deletion of 17p, where the genomic TP53 locus resides (16),
suggesting that TP53 might suppress the expression of miR-155.
To assess this hypothesis, we performed ChIP for TP53 in the
wild-type ALL cell line REH (REH wt) and showed that TP53
binds to one of three predicted binding sites (BS3) downstream
Figure 1.
The effect of miR-155 modulation on drug resistance. A, Cell viability and (B) dose–response curves for A549 cells treated with CDDP (left graph), REH cells (wt and
shp53) treated with doxorubicin (middle) and JM1 cells treated with CDDP (right). C, Clonogenic assay of A549 cells treated with CDDP. D, Viability assay
for H2009 cells treated with CDDP. CDDP, cisplatin; wt, wild-type; shp53, short hairpin for TP53; LVEV, lentivirus empty vector; LV, lentivirus. Error bars, SEM; each
assay was performed at least three times.
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Figure 2.
In vivo orthotopic lung cancer model for the role of miR-155 in chemoresistance.A, Injection and treatment schedule for CDDP (green arrows) and anti-miR-negative
control (NC) or anti-miR-155 liposomal nanoparticles (red stars) for five different treatment groups: mice that were injected with A549-LVEV cells and
untreated (group 1), injected with A549-LVEV cells and treated with anti-miR-NC and CDDP (group 2), injected with A549-155LV cells and treated with anti-miR-NC
andCDDP (group 3), injectedwith A549-155LV cells and treatedwith anti-miR-155 alone (group 4), and injectedwith A549-155LV cells and treatedwith anti-miR-155
and CDDP (group 5). B and C, Graphs of the primary tumor size (B) and the aggregate mass of nodules in the mediastinum (C) for each of the five treatment
groups.D, In situ hybridization formiR-155 for each of the five treatment groups. E, Immunohistochemical analyses for Ki-67 (proliferation) and CD31 (angiogenesis),
as well as the TUNEL assay (apoptosis) and TP53 immunostaining for each of the five treatment groups. Quantifications are presented in the histograms at
the right side of the pictures. CDDP, cisplatin; LVEV, lentivirus empty vector; LV, lentivirus; NC, negative control. Error bars, SEM. Scale bars in D and E, 100 mm.
The number of mice in each group is indicated.
Van Roosbroeck et al.
Clin Cancer Res; 23(11) June 1, 2017 Clinical Cancer Research2898
on March 13, 2019. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst November 30, 2016; DOI: 10.1158/1078-0432.CCR-16-1025 
of miR-155 (Fig. 4A and B). A luciferase reporter assay for BS3
confirmed that TP53 inhibits the expression of miR-155 through
direct binding in the region downstream of miR-155 (Fig. 4C).
The silencing effect was abrogated when BS3 was mutated,
further confirming a direct binding of TP53 to BS3 (Fig. 4C).
To determine whether miR-155 is involved in a feedback loop,
we checked whether overexpression of miR-155 affected TP53
expression. We transfected TP53 wild-type (wt) A549 and H460
cells (42) with miR-155 and observed reduced expression of
TP53 protein, as well as of the known miR-155 target TP53INP1
(43, 44) and CDKN1A (p21) (Fig. 4D). When downregulating
miR-155 in the H2009 lung cancer cell line harboring a mutation
Figure 3.
In vivo toxicology assessment of anti-
miR-155-DOPC. A, Blood chemistry
analyses of BUN, AST, ALT, ALP,
creatinine and LDH in mice (n ¼ 5/
group) treated with anti-miR-NC-DOPC
or anti-miR-155-DOPC. B–C,
Hematology analyses consisting of
complete blood count (B) including
white blood cell (WBC) count, red blood
cell (RBC) count, hemoglobin,
hematocrit, average volume of RBC
(mean corpuscular volume or MCV),
average amount of hemoglobin in one
RBC (mean corpuscular hemoglobin or
MCH), average concentration of
hemoglobin in one RBC (MCHC), red cell
distribution width (RDW) platelet count
andmeanplatelet volume (MPV), aswell
as WBC differential count (C) including
levels of segmented neutrophils,
lymphocytes, monocytes, eosinophils,
basophils and large unstained cells
(LUC) in mice (n ¼ 10/group) treated
with anti-miR-NC-DOPC or anti-miR-
155-DOPC. D, Cytokine assay detecting
25 proinflammatory cytokines in the
serum of mice (n ¼ 10/group) injected
with either anti-miR-NC-DOPC or anti-
miR-155-DOPC. E, H&E staining in brain,
heart, kidney, liver, lung, and spleen of
mice (n ¼ 5/group) treated with anti-
miR-NC-DOPC or anti-miR-155-DOPC.
Neutro, neutrophils; Lymph,
lymphocytes; Mono, monocytes; Eos,
eosinophils; Baso, basophils; LUC, large
unstained cells. Error bars, SD.
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in TP53 that does not affect the miR-155 binding sites, we
observed increased TP53 and CDKN1A (p21) protein expression
(Fig. 4E). A luciferase reporter assay in the TP53-null cell line
H1299 for two identified miR-155 binding sites in the 30 UTR of
TP53mRNA (BS-UTR) (Fig. 4F) and in the TP53 coding sequence
(BS-CDS), respectively, showed a direct binding ofmiR-155 to BS-
UTR (Fig. 4G) but not to BS-CDS (data not shown). The silencing
effect was abolished when BS-UTR was mutated (Fig. 4G), indi-
cating a direct binding of miR-155 to the 30 UTR of TP53. Similar
experiments in the TP53 wild-type cell line H460 showed a
reduction in luciferase activity as well (Fig. 4H). Finally, to assess
the effects of miR-155 overexpression on TP53 expression in vivo,
we performed TP53 immunostaining on the mouse tumors and
observed a decrease in TP53 expression when miR-155 was over-
expressed. Treatment with anti-miR-155 alone did not signifi-
cantly affect TP53 expression, but a combination of anti-miR-155
with CDDP resulted in a significant increase of TP53 expression
(Fig. 2E; Supplementary Fig. S2F). Altogether, these in vitro and in
vivo data demonstrate a negative feedback loop betweenmiR-155
and TP53, which is involved in resistance to chemotherapy.
To understand the biological significance of the newly identi-
fied miR-155/TP53 feedback loop, and to determine how our
findings fit inwith other known functions and targets ofmiR-155,
we performed integrated function and pathway analysis on
248 experimentally validated miR-155 target genes. Thirteen
pathways (Supplementary Table S4) were significantly (P <
0.01 and FDR < 10%) enriched, the majority of which were
related to cancer (pathways in cancer, colorectal cancer, pancreatic
cancer), cell growth and death (cell cycle, apoptosis), as well as
signal transduction pathways often deregulated in cancer and
involved in drug resistance (Wnt signaling pathway, TGFb sig-
naling pathway, signaling by BMP, signaling by NGF). These
pathways closely relate to the roles of miR-155 as an oncogene
(45), TP53 as tumor suppressor and apoptosis inducer (10), and
our novel findings of a miR-155/TP53-negative feedback loop
involved in resistance to therapy.
High expression of miR-155 and low expression of TP53 are
correlated with survival
MiR-155 was found to have a prognostic impact in patients
with various types of cancer (19), including lung cancer (20),
leukemia (17, 18), breast cancer (46), renal cell carcinoma (47),
glioma (48), colorectal cancer (49), and gallbladder carcinoma
(50). We additionally assessed the correlation of miR-155 with
survival in two independent and already published CLL cohorts
(CLL-NEJM, ref. 23; CLL-Clin Cancer Res, ref. 24), in a new ALL
Figure 4.
In vitro validation of amiR-155/TP53-negative feedback loop.A,Schematic representation of three predicted TP53 binding sites in the downstream region ofmiR-155.
B, ChIP for TP53 binding to BS1/2 and BS3 in REH cells with normal TP53 expression (REH wt). C, Luciferase reporter assay and mutagenesis for the TP53
binding site BS3 downstream of miR-155 in A549 cells. D,Western blot analysis of A549 and H460 cell lines with baseline miR-155 levels or overexpressing miR-155.
E, Western blot analysis of H2009 cells with relatively high basal miR-155 expression and after inhibiting miR-155. F, Schematic representation of a predicted
miR-155 binding site in the 30 UTR of TP53 (BS-UTR).G, Luciferase reporter assay andmutagenesis for BS-UTR in the TP53-null cell line H1299. H, Luciferase reporter
assay for the 30 UTR of TP53 in the TP53 wild-type cell line H460. BS, binding site; SCR, scrambled. Error bars, SD; each assay was performed at least three times.
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cohort (ALL-MDACC), and in four lung cancer datasets (two new
cohorts, NSCLC-Italy and lung adenocarcinoma-MDACC, and
the TCGA cohorts for lung adenocarcinoma and squamous cell
carcinoma). To our surprise, we only found a correlation between
high expression of miR-155 in the leukemia datasets (Supple-
mentary Fig. S3), but not in any of the lung cancer cohorts (Table
1). We previously showed that a combination of miR-520d-3p
and its target EphA2 is a better prognostic factor for ovarian cancer
than each gene by itself (31). To investigatewhether this is also the
case for our newly identified miR-155/TP53-negative feedback
loop, we associated miR-155 and TP53 transcript expression with
overall survival (OS) and time-to-progression (TTP) in four sets of
lung cancer (Table 1). We used OS as a measure of resistance to
therapy. In all cohorts, we found a significant decrease in survival
when miR-155 expression was high and TP53 mRNA expression
was low. This was only true for TP53 mRNA, as no significant
associations could be observed in the TCGA lung cancer datasets
between miR-155/TP53 protein expression and survival. Unfor-
tunately, no TP53 expression data were available for any of the
CLL and ALL datasets.
When TP53 mutation status was considered in the lung ade-
nocarcinoma—TCGA subset, only in cases with unmutated (wild-
type) TP53 or with TP53mutations not affecting its function, high
miR-155 expression (Supplementary Fig. S4A and B), as well as a
combination of high miR-155 and low TP53 expression (Sup-
plementary Fig. S4C and S4D), was significantly associated with
shorter OS. Because all tumors in the NSCLC-Italy dataset were
selected for having unmutated TP53, the same can be concluded
for this dataset. Unfortunately, for the lung adenocarcinoma-
MDACC and lung squamous cell carcinoma–TCGA datasets, too
few patients were left to perform this analysis and get a reliable
significance.
Univariate and multivariate analyses containing the miR-155
and TP53 expression data, several known prognostic factors, and
available clinical parameters (Supplementary Table S5), as well as
hazard ratio (HR) calculations using the estimated parameters
from the Cox models (Supplementary Table S6), confirmed that
high miR-155 and low TP53 mRNA expression or high miR-155
expression (when no TP53 expression data were available) were
independently associated with survival in most datasets (Supple-
mentary Tables S5 and S6). This co-occurrence of high miR-155
expression with low TP53mRNA expression appears to be impor-
tant for predicting survival, as in all analyzed lung cancer datasets,
miR-155 expression and TP53mRNAexpression by itself were not
sufficient to be associated with survival. Interestingly, for the
leukemia datasets (in which miR-155 expression alone was sig-
nificantly associated with survival), when consideringmiR-155 as
a continuous variable in the univariate analyses, the significance is
lost for all cohorts, except CLL-Clin Cancer Res (Supplementary
Table S5). This further supports our concept that a combination of
both miR-155 and TP53 expression represents a better marker to
predict survival.
Discussion
Here, we showed for the first time that TP53 and miR-155 are
linked in a new feedback mechanism. Besides miR-155, TP53 has
been found to be involved in other miRNA regulatory loops, for
example, a regulatory feedback loop between TP53miR-329/300/
381/655, and PTTG1 in pituitary tumors (51), a positive feedback
loop between miR-192, MDM2, and TP53 in breast cancer (52),
and a feed-forward loop involvingmiR-17/20a,DAPK3, andTP53
(53). In addition, TP53 is regulated throughmany other mechan-
isms, of which the most important is MDM2, which blocks the
transcriptional activity of TP53 and mediates its ubiquitylation
andproteosomal degradation. In turn, TP53 transactivatesMDM2
expression to maintain or increase the levels of MDM2 as is
appropriate (54). Furthermore, TP53 has two family members,
TP63 and TP73, which share significant homology with TP53 and
which have several common targets as well as similar tumor
suppressive activities as TP53. All three TP53 family members
have been found to be involved in chemoresistance (reviewed in
refs. 55–57). Moreover, although not yet validated, miR-155
has predicted target sites in TP63, TP73, and MDM2 as well
(miRWalk2.0). This suggests that the actual involvement of
miR-155 in chemoresistance is most likely far more complicated
than the simple miR-155/TP53 feedback mechanism we describe
here. To which extent MDM2 and the TP53 familymembers TP63
and TP73 are involved in miR-155-mediated chemoresistance
warrants further investigation.
We further demonstrated that themiR-155/TP53 feedback loop
is involved in resistance to multiple chemotherapeutic drugs
used in treatment combinations in lung cancer (6) and leukemia
(38, 58). Through miR-155 downregulation in vivo, we success-
fully resensitized the tumors to chemotherapy and, therefore, this
miR-155/TP53 interactor loop could be exploited for miRNA-
based therapeutic interventions in cancer patients (59, 60).Others
have shown that LNA-based and nanoparticle-based inhibition of
miR-155 decreases tumor growth in mouse models of Walden-
strom macroglobulinemia and lymphoma, respectively (61–63).
In addition, a recent publication showed that knockdown ofmiR-
155 in the doxorubicin-resistant cell line A549/dox reversed
doxorubicin resistance and restored doxorubicin-induced apo-
ptosis and cell-cycle arrest,most likely through downregulation of
multidrug resistance genes (MDR1 and MRP1) and the breast
cancer resistance protein gene (BCRP; ref. 64), further supporting
that miR-155 might be a good target in chemosensitization of
tumors.
Our in vivo toxicology studies did not uncover any adverse
effects of anti-miR-155-DOPC in mice. These findings are impor-
tant, especially in light of the recent early termination of the phase
I clinical study of MRX34, the first miRNA-based therapy to be
evaluated in clinical trials for the treatment of human cancers, due
to multiple immune-related severe adverse events observed
in patients receiving MRX34 (ClinicalTrial.gov Identifier
NCT01829971). Our approach is to combine chemotherapy with
targeted anti-miR-155 therapy, which will significantly reduce the
risks of adverse events, since lower doses of bothdrugswill need to
be used to achieve clinical responses. In addition, the used carrier
molecule, DOPC liposomal nanoparticles, is currently being
tested in a phase I clinical trial (ClinicalTrial.gov Identifier
NCT01591356), and so far, no adverse events have been associ-
ated with the treatment. This suggests that treatment with anti-
miR-155-DOPC will most likely be safe and well tolerated.
However, further systematic preclinical safety studies for anti-
miR-155-DOPC in large animals are needed before its clinical
value can be evaluated.
When we took the TP53 mutational status into consideration
for the survival analysis of the lung adenocarcinoma–TCGA
cohort, we observed that miR-155 and the combination of
miR-155 and TP53 are significantly associated with shorter OS,
only in cases with unmutated TP53 or TP53 mutations not
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affecting its function. Similar conclusions could be drawn from
the NSCLC-Italy cohort, because all patients were selected for
unmutated TP53 status. In addition, we showed that overexpres-
sion of miR-155 in MEC1 and MEC2 cell lines (both carrying a
deletion of the TP53 locus) does not induce chemoresistance to
fludarabine treatment (Supplementary Fig. S1), suggesting that
there is a difference in response in the context of wild-type and
mutant TP53 alleles. However, as the current data are very limited,
further investigation is needed to assess the role of mutant TP53
versus wild-type TP53 in the newly identified miR-155/TP53
feedback loop.
In contrast withmost of the literature (meta-analyses in refs.19,
20, and65),we found that inmost of the analyzed cancer datasets,
miR-155 expression and TP53mRNAexpression by itself were not
sufficient to be associated with OS (Table 1). In fact, significant
correlations between miR-155 and survival could only be found
in the leukemia cohorts. In addition, a recent meta-analysis
evaluating miR-155 as a prognostic factor for survival in 1,557
NSCLC patients from 6 different studies suggested that high
expression levels of miR-155 alone may not be significantly
related to lung cancer prognosis, except for Asian and American
patients (66). Our data further support the importance to con-
sider miRNA (miR-155) and target mRNA (TP53) to predict
survival. Actually, when combined, we found that high miR-
155 and lowTP53 expression significantly correlatedwith survival
in 4 independent lung cancer datasets (Table 1), and that this
combination remained independently associated with survival in
the datasets analyzed in a multivariate analysis (Supplementary
Tables S5 and S6). We recently demonstrated that a combination
of miR-520d-3p and its target EphA2 is a better prognostic factor
for ovarian cancer than each gene by itself, and that simultaneous
targeting of miRNA/mRNA (miR-520d-3p/EphA2) results in a
remarkable therapeutic synergy as compared with either mono-
therapy (31).
In conclusion, our study is innovative due to multiple reasons.
We show for the first time that themost frequently altered human
tumor suppressor TP53 is directly targeted by one of the most
oncogenic miRNAs,miR-155, and that TP53 directly regulates the
expression of this miRNA as a feedback loop. Second, a combi-
nation of TP53 andmiR-155 expression seems to be amuch better
classifier for overall survival of lung cancer and possibly also
leukemia, than miR-155 alone. Third, miR-155 and TP53 and
their downstream targets are involved in resistance to multiple
types of chemotherapeutic regimens in various hystotypes. Final-
ly, we propose to use anti-miR-155 as an additive to chemother-
apy and not as a single agent, as was proposed by others (61–63).
Thismeans lower doses of drugs tobeused and, consequently, less
adverse reactions to occur in clinical trials. The identification of
the miR-155/TP53 interaction will favor the advancement of new
anti-miR-155-targeted therapies to overcome the development of
drug resistance.
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